ProMIS is a development stage biotech company harnessing the power of precision medicine to conquer Alzheimer?s disease and ALS. ProMIS_ Neurosciences (TSE: PMN), discovers and develops precision therapeutics and companion diagnostics for early detection and effective treatment of neurodegenerative diseases, in particular Alzheimers disease & Amyotrophic Lateral Sclerosis.
ProMIS Neurosciences, Inc.
[stock_market_widget type=”leaderboard” template=”color-frame” color=”yellow” assets=”PMN.TO” api=”yf” style=”font-size: 15px”]
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://in.linkedin.com/company/promis-neurosciences” connections=”true” suffix=””]
ProMIS Neurosciences uses its computational discovery platform, ProMIS_, to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Company owns exclusive rights to the Genus patent relating to misfolded SOD1 in ALS, and currently has a preclinical monoclonal antibody therapeutic directed against this target.
In May 2018,ProMIS Neurosciences closes $7.2 million private placement o.f 19,306,668 Units at the price of CDN$0.375 per Unit